Enteral formulation: low in fat and containing protein hydrolysa

Details Enteral formulation: low in fat and containing protein hydrolysa Enteral formulation: low in fat and containing protein hydrolysa

1995-10-27

1998-10-13

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 23, 514 54, 514 60, 514549, 514552, 514558, 514560, A61K 3800, A61K 3170, A61K 31715, A61K 3122, A61K 3123, A61K 3120

Patent

active

058212175

ABSTRACT:
An improved enteral formulation that is low in fat and contains protein hydrolysates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H.sub.2 O, preferably about 300 mOs/kg H.sub.2 O. In a preferred embodiment, the formulation contains corn starch to control blood glucose levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients.

REFERENCES:
patent: 3698912 (1972-10-01), Winitz
patent: 4438144 (1984-03-01), Blackburn
patent: 4528197 (1985-07-01), Blakburn
patent: 4959350 (1990-09-01), Frokjaer et al.
patent: 5106836 (1992-04-01), Clemens et al.
patent: 5189016 (1993-02-01), Madsen et al.
patent: 5229136 (1993-07-01), Mark et al.
patent: 5298493 (1994-03-01), Mendy
patent: 5403972 (1995-04-01), Valentine, Sr.
patent: 5405835 (1995-04-01), Mendy
patent: 5438042 (1995-08-01), Schmidl et al.
patent: 5545411 (1996-08-01), Chancellor
Donald, P., et al., "Repletion of Nutritional Parameters in Surgical Patients Receiving Peptide Versus Amino Acid Elemental Fedings," Nutrition Research, vol. 14, 3-12 (1994);.
Dutton, E., et al., "Medium-Chain Triglycerides in Neonatal Nutrition," American Journal of Perinatology, vol. 4, No. 1, 5-7 (1987);.
Hamilton, C., et al., "Protocol Decreases Enteral Feeding Complications," 17th Clinical Congress Abstracts, vol. 17, No. 1, supplement, 31S (Jan.-Feb. 1993);.
Heimburger, D.C. et al., "Tolerance and Efficacy of Small-Peptide Enteral Feeding Formula VS. Isocaloric, Isonitrogenous Whole-Protein Formula," 18th Clinical Congress Abstracts, vol. 18, No. 1, supplement, 21S (Jan.-Feb. 1994);.
McBurney, M.I. et al., "Effect of Soy Polysaccharide (SP) Supplementation of Total Enteral Nutrition (TEN) Formulas on Large Bowel Short Chain Fatty Acid (SCFA) Production in Humans," 16th Clinical Congress Abstracts, vol. 16, No. 1, supplement, 18S (Jan.-Feb. 1992);.
Mowatt-Larssen, C.A., "Enteral Nutrition Efficacy and Tolerance Comparison of Peptide with Standard Formulas," 15th Clinical Congress Abstracts, vol. 15, No. 1, supplement, 32S (Jan.-Feb. 1991);.
Simko, V., et al., "Absorption of Diffrent Elemental Diets in a Short-Bowel Syndrome Lasting 15 Years," Digestive Diseases, vol. 21, No. 5, 419-425 (1976).

Affiliated with

Also associated with

Rating

Enteral formulation: low in fat and containing protein hydrolysa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enteral formulation: low in fat and containing protein hydrolysa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enteral formulation: low in fat and containing protein hydrolysa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-313233